Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan

Table 1 Selected phase II and III trials of first-line non-platinum-based chemotherapy for patients with advanced gastric cancer

Ref.	Year	Phase	Tx	Dose (mg/m2 per day)	Cycle	Patients (n)	RR	Median TTP/TTF/PFS (mo)	Median OS (mo)	P value for OS
Vanhoefer et al[37]	2000	III	FAM	(5FU: 1500, A: 30, M: 1500)	(D1, D1, and D15, 4 wk)	85	12%	3.3	6.7	-
			FC	(F: 1000, C: 100)	(D1-5 and D2, 4 wk)	81	20%	4.1	7.2	0.77
			ELF	(L: 300, E: 120, F: 500)	(D1-5, 3 wk)	79	9%	3.3	7.2	0.73
Boku et al[18]	2009	III	F	F: 800	D1-5, 4 wk	234	-	2.9	10.8	-
			IC	(I: 70, C: 80)	(D1,15 and D1, 4 wk)	236	-	4.8	12.3	0.0551
			S	S: 80	D1-28, 6 wk	234	-	4.2	11.4	< 0.0012
Ohtsu et al[19] (JCOG 9205)	2003	III	F	F: 800	D1-5, 4 wk	105	11.4%	1.9	7.1	-
			FC	(F: 800, C: 20)	(D1-5 and D1-5, 4 wk)	105	34.3%	3.9	7.6	0.34
			U/T3	U/T: 750	-	70	8.6%	2.4	6.0	0.11
Kim et al[59]	2005	II	DX	D: 75	D1, 3 wk	32	43.8%	5.1	8.4	-
				X: 2000	D1-14, 3 wk
Giordano et al[60] (NCCTG)	2006	II	DX	D: 75	D1, 3 wk	44	39%	4.2	9.4	-
				X: 1650	D1-14, 3 wk
Jeung et al[54]	2011	II (random)	DS	(D: 35, S: 70)	(D1, 8 and D1-14, 3 wk)	39	46%	7.3	16.0	0.019
			DC	(D: 35, C: 35)	(D1, 8 and D1, 8, 3 wk)	41	24%	4.8	8.2
Park et al[50]	2006	II (random)	PF	(P: 175, F: 500)	(D1 and D1-5, 3 wk)	38	42%	3.6	9.9	-
			DF	(D: 75, F: 500)	(D1 and D1-5, 3 wk)	39	33%	4.2	9.3
Mochiki et al[44]	2012	II (random)	SP	(S: 80, P: 60)	(D1-14 and D1, 8, 15, 4 wk)	42	52.3%	9.0	16.0	0.084
			SC	(S: 80, C: 60)	(D1-21 and D8, 5 wk)	41	48.7%	6.0	17.0
Pozzo et al[51]	2004	II (random)	ILF	(I: 80, L: 500, F: 2000)	(D1, weekly, 6 wk)	74	42.4%	6.5	10.7	0.0018
			IC	(I: 200, C: 60)	(D1 and D1, 3 wk)	72	32.1%	4.2	6.9
Narahara et al[48] (GC0301/TOP-002)	2011	III	IS	(S: 80, I: 80)	(D1-21, 5 wk, D1 and 15, 5 wk)	164	41.5%	4.5	12.8	0.233
			S	S: 80	D1-28, 6 wk	162	26.9%	3.6	10.5
Moehler et al[46]	2010	II (random)	IX	(I: 250, X: 2000)	(D1 and D1-14, 3 wk)	57	37.7%	4.2	10.2	-
			CX	(C: 80, X: 2000)	(D1 and D1-14, 3 wk)	55	42.0%	4.8	7.9
Oh et al[49]	2007	II	IX	(I: 130, X: 3500)	(D1,15 and D1-15, 3 wk)	55	43.6%	5.0	11.0	-
Baek et al[55]	2006	II	IX	(I:100, X: 2000)	(D1, 8 and D1-14, 3 wk)	41	46.3%	5.1	8.6	-
Bouché et al[57] (FFCD 9803)	2004	II	LF	(L: 200, F: 400/600)	(D1-2, 2 wk)	45	13%	3.2	6.8	-
			LFC	(L: 200, F: 400/600, C: 50)	(D1-2, 2 wk)	44	27%	4.9	9.5
			LFI	(F: 200, F: 400/600, I: 180)	(D1-2, 2 wk)	45	40%	6.9	11.3
Dank et al[58]	2008	III	IFL	(I: 80, L: 500, F: 2000)	(D1, weekly, 6 wk)	172	31.8%	5.0	9.0	0.53
			CF	(C: 100, F:1000)	(D1 and D1-5, 4 wk)	165	25.8%	4.2	8.7

¹Superiority compared to 5-fluorouracil (5FU) alone;

²Non-inferiority compared to 5FU alone;

³With weekly bolus infusion of mitomycin 5 mg/m². Tx: Treatment; TTP: Time to progression; TTF: Time to treatment failure; PFS: Progression-free survival; OS: Overall survival; F: 5FU; A: Adriamycin; M: Methotrexate; C: Cisplatin; E: Etoposide; L: Leucovorin; I: Irinotecan; S: S-1; U/T: Uracil and tegafur; D: Docetaxel; X: Capecitabine; P: Paclitaxel.